DrugMapper
  • Browse
    • Therapeutic Area
      • CANCER (51)
      • CARDIOVASCULAR (45)
      • DENTISTRY (2)
      • DERMATOLOGY (31)
      • DIABETES DRUGS & ENDOCRINOLOGY (61)
      • EMERGENCY MEDICINE (3)
      • ENT (5)
      • EYE (23)
      • GASTROINTESTINAL (29)
      • HEMATOLOGY (23)
      • MUSCULOSKELETAL (28)
      • NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
      • PEDIATRICS (27)
      • PHARMACOLOGY (8)
      • PREGNANCY AND GYNECOLOGY (30)
      • RESPIRATORY (42)
      • RHEUMATOLOGY (19)
      • OTHER (1482)
    • Therapeutic Indication
    • Adverse Reaction (System Organ Classification)
    • Mechanism of Action
    • Primary Target
    • Target Level
      • Level 1
      • Level 2
      • Level 3
      • Level 4
      • Level 5
      • Level 6
    • Active Pharmaceutical Ingredients (APIs)
    • Small Molecules
    • ProDrugs
    • Antibodies
    • CNS drugs
    • Metabolites
  • Search
      Therapeutic Indication Adverse Reaction (System Organ Classification)
      Mechanism of Action Target Sequence
      Chemical Structure Physicochemical Properties
  • Analyze

      Networks

    • Chemical Similarity
    • Scaffold Similarity
    • KNIME workflow
  • Downloads
      Web services Bulk Downloads
  • About
      DrugMapper FAQs Data Sources Contact Us

VON WILLEBRAND FACTOR HUMAN

Search structure
Synonyms:
HUMAN VON WILLEBRAND FACTOR
VON WILLEBRAND FACTOR
VON WILLEBRAND FACTOR (HUMAN)
VON WILLEBRAND FACTOR, HUMAN
VON WILLEBRAND FACTOR HUMAN COMPONENT OF VONCENTO
VON WILLEBRAND FACTOR HUMAN COMPONENT OF VONCENTO VON WILLEBRAND FACTOR
VON WILLEBRAND FACTOR HUMAN COMPONENT OF WILATE
VON WILLEBRAND'S FACTOR
Status: Approved
Entry Type: Unknown
Molecule Category: UNKNOWN
UNII: ZE22NE22F1

Indications

Mesh Heading Maximum Phase Mesh ID Reference
von Willebrand Diseases 3 D014842 ClinicalTrials
Postpartum Hemorrhage 3 D006473 ClinicalTrials
von Willebrand Diseases 3 D014842 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL4298126
FDA SRS ZE22NE22F1
CONTENTS
  • Structure
  • Indications
  • Cross References
×
70